HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cosmetic CBD Has Insurance Industry Spooked: The Dope Before You Toke

Executive Summary

Marketing CBD-containing cosmetics in today’s hazy legal and regulatory environment carries risks beyond what insurance carriers may be willing to take on. Kenneth Hegel of Cosmetic Insurance Services, a division of brokerage firm Frenkel & Company – an Epic Company, discusses the dilemma facing underwriters and criteria companies can meet to improve their insurance prospects.

You may also be interested in...



CBD Cosmetics Rush Is ‘Fast And Furious,’ But Don’t Skimp On Testing, Experts Say

Speakers at ICMAD’s regulatory workshop in New York stressed the importance of CBD testing in today’s highly uncertain climate for hemp-based cosmetics. While rigorous testing can drive up costs and slow the path to market, it also could significantly reduce chances of safety, regulatory or legal issues down the line.

Interested In Using CBD Or Probiotics In Cosmetics? Ask Yourself Why – FDA’s Linda Katz

The answer to the ‘why’ question can help clarify whether a company is marketing a cosmetic or an unapproved drug, FDA’s cosmetics office director advised attendees at ICMAD’s 38th annual regulatory workshop in New York.

Cosmetics Firms ‘Chomping At The Bit’ To Use CBD, But Do So At Own Peril, Attorney Says

Tucker Ellis attorney Ronie Schmelz discusses uncertainties companies face in marketing CBD-containing cosmetics and measures they can take to mitigate risks ahead of expected regulatory guidance.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel